tiprankstipranks
Trending News
More News >
Dermata Therapeutics (DRMA)
NASDAQ:DRMA
US Market

Dermata Therapeutics (DRMA) Stock Forecast & Price Target

Compare
149 Followers
See the Price Targets and Ratings of:

DRMA Analyst Ratings

Currently, no data available
Based on NaN analysts giving stock ratings to
Dermata
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

DRMA Stock 12 Month Forecast

There Are No Analyst Ratings for DRMA In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

DRMA Financial Forecast

DRMA Earnings Forecast

Next quarter’s earnings estimate for DRMA is -$1.54 with a range of -$1.54 to -$1.54. The previous quarter’s EPS was -$1.65. DRMA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year DRMA has Performed in-line its overall industry.
Next quarter’s earnings estimate for DRMA is -$1.54 with a range of -$1.54 to -$1.54. The previous quarter’s EPS was -$1.65. DRMA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year DRMA has Performed in-line its overall industry.
No data currently available

DRMA Sales Forecast

The previous quarter’s earnings for DRMA were $0.00.
The previous quarter’s earnings for DRMA were $0.00.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Maxim Group Analyst forecast on DRMA
Maxim Group
Maxim Group
$10
Buy
367.29%
Upside
Reiterated
11/25/25
Dermata Therapeutics: Strategic Shift and Financial Stability Support Buy Rating
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Maxim Group Analyst forecast on DRMA
Maxim Group
Maxim Group
$10
Buy
367.29%
Upside
Reiterated
11/25/25
Dermata Therapeutics: Strategic Shift and Financial Stability Support Buy Rating
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Dermata Therapeutics

3 Months
xxx
Success Rate
4/21 ratings generated profit
19%
Average Return
-34.28%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 19.05% of your transactions generating a profit, with an average return of -34.28% per trade.
1 Year
Anthony VendettiMaxim Group
Success Rate
0/21 ratings generated profit
0%
Average Return
-82.36%
reiterated a buy rating 4 months ago
Copying Anthony Vendetti's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -82.36% per trade.
2 Years
xxx
Success Rate
0/21 ratings generated profit
0%
Average Return
-91.99%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -91.99% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DRMA Analyst Recommendation Trends

Rating
Sep 25
Nov 25
Dec 25
Jan 26
Feb 26
Strong Buy
5
5
3
2
0
Buy
0
0
0
0
0
Hold
0
0
1
9
24
Sell
0
0
0
3
6
Strong Sell
0
0
0
0
0
total
5
5
4
14
30
In the current month, DRMA has received 0 Buy Ratings, 24 Hold Ratings, and 6 Sell Ratings. DRMA average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.

DRMA Stock Forecast FAQ

What is DRMA’s average 12-month price target, according to analysts?
Currently, no data Available
What is DRMA’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for DRMA, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is DRMA a Buy, Sell or Hold?
      Currently, no data Available
      What is Dermata Therapeutics’s price target?
      Currently, no data Available
      What do analysts say about Dermata Therapeutics?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of DRMA?
      Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.